Searched for
GENERIC ANTIBIOTICS
For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- India bans 16 fixed-dose drug combinations over safety concernsIn a significant public health initiative, the ban on 16 fixed-dose drug combinations, including various antibiotics and topical formulatio...
- Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Wockhardt exits US generics biz to focus on drug discoveryWockhardt is set to exit its loss-making US generics business to prioritize innovation, focusing on new antibiotic drug discovery and its b...
- Aurobindo Pharma gets USFDA nod for antibiotic drugAurobindo Pharma has received final approval from the US health regulator to market its generic antibiotic drug Vancomycin Hydrochloride fo...
- Drug resistance rising; pharma companies must invest in R&D: Jim O'Neill, Goldman SachsWe need to either force or encourage pharma cos to think it is in their own long-term interest to start trying to devote more money into pr...
- Lupin falls over 4% in two sessions on Suprax generic concernsShares of Lupin have extended losses for second straight session after the USFDA allowed Aurobindo Pharma to sell a generic antibiotic drug...
- Government making efforts to bring down price of drugs: Health Minister JP NaddaNadda said the government is trying to regulate the prices of drugs and make medicines more affordable for the people.
- Dr Reddy's launches Amoxicillin tablets, capsules in US marketDr Reddy's today announced the launch of antibiotic Amoxicillin tablets, capsules and oral suspension.
- Lupin Pharmaceuticals gets final USFDA nod for generic antibioticsThe approval by the USFDA has been granted to the company's subsidiary, Lupin Pharmaceuticals Inc for tablets of 65 mg, 80 mg, 105 mg and 1...
- Pharma cos inject capacities to meet growing demandIndian pharmaceutical companies with a presence in sterile injectables space are expanding capacities to cater to growing demand in this se...
- Orchid gets USFDA nod for CefdinirDrug maker Orchid Chemicals and Pharmaceuticals on Friday said it has received USFDA approval for its antibiotic Cefdinir.
- Orchid gets USFDA nod to launch TerbinafineOrchid Chemicals and Pharmaceuticals Ltd on Friday said it has received tentative approval from US Food and Drug Administration.
- 3 cos sue Wyeth over Zosyn patentThree generic pharmaceutical companies, including one from India, have taken legal action against US pharma major Wyeth.
Load More
